We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+4.78%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$55.1M
(+13%)
Cap. Flow
+$73.1M
Cap. Flow
% of AUM
15.11%
Top 10 Holdings %
Top 10 Hldgs %
57.22%
Holding
53
New
11
Increased
11
Reduced
16
Closed
15
Avg Time Held Equity + Options
4.3
quarters
Top 10 Avg Time Held Equity + Options
4.3
quarters
Top 20 Avg Time Held Equity + Options
4.5
quarters
Avg Time Held Equity only
4.3
quarters
Top 10 Avg Time Held Equity only
4.3
quarters
Top 20 Avg Time Held Equity only
4.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procept Biorobotics
PRCT
|
+$43.2M |
| 2 |
Janux Therapeutics
JANX
|
+$35.9M |
| 3 |
Nektar Therapeutics
NKTR
|
+$31M |
| 4 |
Veeva Systems
VEEV
|
+$23.9M |
| 5 |
Phreesia
PHR
|
+$20.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuitive Surgical
ISRG
|
+$21.8M |
| 2 |
BridgeBio Pharma
BBIO
|
+$15.4M |
| 3 |
Roivant Sciences
ROIV
|
+$14M |
| 4 |
DexCom
DXCM
|
+$13.1M |
| 5 |
Immunovant
IMVT
|
+$10.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.58% |
| 2 | Industrials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Procept Biorobotics
PRCT
$1.09B
| $43.4M | 8.97% |
1,380,000
+1,303,009
| +1,692% | +$43.2M |
2025 Q3
1 quarter
|
|
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $35.1M | 7.26% |
1,074,112
-75,888
| -7% | -$2.45M |
2021 Q1
19 quarters
|
|
|
3
Janux Therapeutics
JANX
$1.05B
| $33M | 6.82% |
2,392,523
+1,527,173
| +176% | +$35.9M |
2024 Q3
5 quarters
|
|
4
ADC Therapeutics
ADCT
$217M
| $29.9M | 6.18% |
8,477,338
+1,005,035
| +13% | +$4.08M |
2022 Q3
13 quarters
|
|
5
Kura Oncology
KURA
$874M
| $26.3M | 5.43% |
2,529,600
-228,916
| -8% | -$2.4M |
2023 Q2
10 quarters
|
|
6
MeiraGTx Holdings
MGTX
$955M
| $25.5M | 5.27% |
3,209,788
-879,721
| -22% | -$7.31M |
2022 Q1
15 quarters
|
|
|
7
Nektar Therapeutics
NKTR
$1.29B
| $23.4M | 4.85% |
+554,633
| New | +$31M |
2025 Q4
0 quarters
|
|
|
8
Veeva Systems
VEEV
$48.8B
| $20.1M | 4.16% |
+90,133
| New | +$23.9M |
2025 Q4
0 quarters
|
|
9
Icon
ICLR
$12.7B
| $20M | 4.14% |
110,000
+500
| +0.5% | +$89K |
2024 Q4
4 quarters
|
|
10
Boston Scientific
BSX
$62.8B
| $20M | 4.14% |
210,000
+133,900
| +176% | +$13.1M |
2025 Q3
1 quarter
|
|
11
Concentra Group Holdings
CON
$4.79B
| $17.5M | 3.62% |
891,030
+281,030
| +46% | +$5.62M |
2025 Q2
2 quarters
|
|
|
12
Phreesia
PHR
$667M
| $16.5M | 3.42% |
+977,152
| New | +$20.2M |
2025 Q4
0 quarters
|
|
13
DELISTED
Amicus Therapeutics
FOLD
| $16.4M | 3.38% |
1,150,000
-559,533
| -33% | -$5.5M |
2024 Q4
4 quarters
|
|
14
DELISTED
Select Medical
SEM
| $15.4M | 3.18% |
1,035,086
+160,171
| +18% | +$2.26M |
2025 Q2
2 quarters
|
|
15
Syndax Pharmaceuticals
SNDX
$1.25B
| $14M | 2.89% |
665,000
-338,400
| -34% | -$5.9M |
2024 Q2
6 quarters
|
|
16
Zymeworks
ZYME
$1.8B
| $14M | 2.89% |
530,393
-219,218
| -29% | -$4.78M |
2024 Q1
7 quarters
|
|
|
17
Roivant Sciences
ROIV
$24.1B
| $13.6M | 2.81% |
627,162
-708,338
| -53% | -$14M |
2024 Q1
7 quarters
|
|
18
DELISTED
Crinetics Pharmaceuticals
CRNX
| $12.2M | 2.53% |
262,904
-65,780
| -20% | -$2.93M |
2025 Q2
2 quarters
|
|
19
Avantor
AVTR
$10.5B
| $10.3M | 2.13% |
+898,499
| New | +$11.1M |
2025 Q4
0 quarters
|
|
20
Shattuck Labs
STTK
$551M
| $8.69M | 1.8% |
2,381,502
-3,069,693
| -56% | -$7.32M |
2021 Q3
17 quarters
|
|
21
Labcorp
LH
$25.4B
| $8.66M | 1.79% |
+34,532
| New | +$9.17M |
2025 Q4
0 quarters
|
|
22
GeneDx Holdings
WGS
$1.94B
| $7.15M | 1.48% |
+55,000
| New | +$7.55M |
2025 Q4
0 quarters
|
|
23
Alnylam Pharmaceuticals
ALNY
$29.9B
| $6.8M | 1.41% |
+17,109
| New | +$7.57M |
2025 Q4
0 quarters
|
|
|
24
Immunovant
IMVT
$5.93B
| $6.19M | 1.28% |
243,404
-455,068
| -65% | -$10.1M |
2024 Q1
7 quarters
|
|
25
Corbus Pharmaceuticals
CRBP
$92.5M
| $5.57M | 1.15% |
683,872
+340,472
| +99% | +$4.2M |
2024 Q3
5 quarters
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q4 2025 Portfolio in Review
As of Q4 2025, Prosight Management held 53 positions worth $484M, up 13% from $429M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Prosight Management deployed $73.1M of net new capital in Q4 2025, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Nektar Therapeutics: 554,633 shares worth $23.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was BridgeBio Pharma, an estimated $15.4M trimmed.
- Prosight Management's largest Q4 2025 buy was Nektar Therapeutics: 554,633 shares worth $23.4M.
- Prosight Management added most to Procept Biorobotics in Q4 2025, an estimated $43.2M increase.
- Prosight Management's biggest Q4 2025 reduction was BridgeBio Pharma, cutting an estimated $15.4M.
- Prosight Management fully exited Intuitive Surgical in Q4 2025, selling an estimated $21.8M.
- Prosight Management's ten largest holdings make up 57% of its $484M portfolio in Q4 2025.
- Prosight Management opened 11 new positions and closed 15 in Q4 2025.
- Prosight Management's portfolio value rose 13% quarter-over-quarter to $484M.
Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.